Oral PCSK9 Inhibitors
Document Type
Article
Publication Title
Current Artherosclerosis Reports
Abstract
Purpose of review: In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Recent findings: The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations, the most advanced of which is MK-0616. MK-0616 is a novel, orally administered macrocyclic peptide that binds to PCSK9 and inhibits binding of PCSK9 to the LDL receptor, thereby decreasing plasma levels of LDL-C. Clinical trial data on the safety and efficacy of MK-0616 are promising and report LDL-C-lowering efficacy comparable to that provided by injectable PCSK9 inhibitors. Ongoing and future studies of oral PCSK9 inhibitors in development will evaluate the safety, efficacy, and effectiveness of these agents and their potential role in preventing cardiovascular disease events.
DOI
10.1007/s11883-024-01199-2
Publication Date
3-27-2024
Keywords
Drug development, Lipid-lowering therapy, PCSK9 inhibitors
ISSN
1534-6242
Recommended Citation
Agarwala A, Asim R, Ballantyne CM. Oral PCSK9 Inhibitors. Current Artherosclerosis Reports. 2024; . doi: 10.1007/s11883-024-01199-2.
